Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow the degenerative processes associated with aging and improve the functional results of patients suffering from age-related diseases, announces today that it has received feedback from the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) allowing it to plan the next regulatory steps for its COVA project dedicated to the development of Sarconeos (BIO101) in severe forms of Covid-19.